Citations

Clear

3942 citation(s) found for "To, Van".

Meta-analysis of atherosclerosis in formerly pre-eclamptic women
Rooy, A De, Janssen, Emma B N J , Altintas, Sibel , Spaanderman, Marc E. A. , Jansen, Gerrit , Hof, Arnoud W.J. van ’t , Mihl, Casper , Kietselaer, Bas , Ghossein‐Doha, Chahinda

Mayo Clinic

European Journal of Preventive Cardiology | May 19, 2025 | Volume: 32 | Issue: Supplement_1 | Pages: No page available

10.1093/eurjpc/zwaf236.463 Get It

Abstract Background Up to eight percent of pregnant women have pre-eclampsia. These women have an increased risk of future ischemic heart and cerebral disease. This warrants early cardiovascular risk management in early disease stages. This meta-analysis determines how the prevalence of subclinical atherosclerosis in women after pre-eclamptic compared to non-pre-eclamptic pregnancies changes over time. Methods A systematic search was used. Studies reporting the prevalence of systemic atherosclerosis using ultrasound or computed tomography in formerly pre-eclamptic and non-pre-eclamptic women were included. A random-effects meta-analysis provided overall odds ratio’s (OR (95% confidence interval (CI)) for the association between pre-eclampsia and the prevalence of atherosclerosis. Results Eleven articles could be included with a total of 13,217 participants. Maternal age ranged from 33 to 60 years. Within this age period, pooled OR of developing atherosclerosis after pre-eclampsia was 1.57 (95%CI 1.39-1.78). The pooled odds of developing atherosclerotic plaque after a pre-eclamptic versus a non-pre-eclamptic pregnancy increased gradually with age. The odds ratio was not significantly different in the 30-39 age group (OR 0.64 (95%CI 0.10-4.15)), but there was a statistically significantly increased odds of finding an atherosclerotic plaque in the 40-49 (OR 1.59 (95%CI 1.34-1.89)) and 50-60 age groups (OR 2.00 (95%CI 1.30-3.08)) after pre-eclamptic pregnancies compared to non-pre-eclamptic pregnancies. Conclusions Formerly pre-eclamptic women have earlier and more frequent atherosclerosis and occurs ten years earlier than in non-pre-eclamptic women. Targeted prevention strategies are required to prevent premature cardiovascular disease morbidity and mortality in formerly pre-eclamptic women.
The International Classification of Vestibular Disorders: Achievements, challenges, and future directions
Kaski, Diego , Tarnutzer, Alexander A. , Carey, John P. , Cha, Yoon‐Hee , Eggers, Scott D.Z. , Furman, Joseph M. , Kim, Hyun Ah , Lempert, Thomas , López‐Escámez, José A. , Magnusson, Måns , Newman‐Toker, David E. , Seemungal, Barry M. , Berg, Raymond van de , Brevern, Michael von , Bisdorff, Alexandre , Cha, Y H , Eggers, Scott Dz, Lempert, Thomas , López-Escámez, Jose A , Magnusson, Mans , Newman-Toker, David E , Seemungal, Barry M , Staab, Jeffrey P , Agrawal, Yuri , Kim, Ji‐Soo , Staab, Jeffrey P. , Strupp, Michael Leo , Ward, Bryan Kevin

Mayo Clinic

Journal of Vestibular Research | May 17, 2025 | Volume: 35 | Issue: 3 | Pages: 105-112

10.1177/09574271251313803 | PMID 39973600 Get It

In 2007, the Bárány Society embarked on a project to establish definitions of vestibular syndromes and disorders based on best available evidence, referred to as the International Classification of Vestibular Disorders (ICVD). Since then, numerous publications providing consensus-driven diagnostic criteria for vestibular symptoms, syndromes, and disorders have been published. Here, we reflect on the rationale for developing the ICVD as well as its subsequent achievements, challenges, and outlook. In this summary of the work of the ICVD to date, the authors will focus on practical aspects to help improve the utility and applicability of these diagnostic criteria moving forward.
Outcomes and Characteristics of Mesenchymal Tumors Involving the Parotid Gland
Baratz, Hannah , Moore, Eric J. , Molligan, Jeremy , Tasche, Kendall K. , Abel, Kathryn M. Van , Baratz, Hannah Q , Yin, Linda X , Van Abel, Kathryn M , Yin, Linda X. , Price, Daniel L.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | May 15, 2025 | Volume: 134 | Issue: 8 | Pages: 583-587

10.1177/00034894251336840 | PMID 40370050 Get It

Background: Malignant mesenchymal tumors involving the parotid gland are uncommon, characteristically aggressive, and little is known with few reports documented. Study Design: Retrospective case series. Setting: Single institution tertiary care center, 2010 to 2022. Method: Patients were identified from an institutional parotid tumor database. Patient history, demographics, pathologic diagnosis, treatment, and follow up were documented. Results: Eight patients were identified, 3 were males. The average age was 61 years old, and the most common tumors identified were pleomorphic sarcomas (3 patients). Presenting symptoms included: preauricular/cheek mass in 7 patients, facial pain (4), otalgia (4), aural fullness (3), and numbness (1). All patients received a parotidectomy, and 4 patients received adjuvant therapy of either radiation or chemoradiation. Post-operatively, there were 3 cases of distant recurrence, 2 cases of regional recurrence, and 1 case of local recurrence. There were 2 reports of death. Conclusion: Malignant mesenchymal tumors of the parotid are rare, represent varied histologies. Due to their aggressive nature, surgical resection with radiation and close follow-up may be an appropriate treatment regimen in controlling the disease.
Postoperative ctHPVDNA Kinetics in Patients With HPV-Related Oropharyngeal Cancer
Hidalgo, C. , Bogan, Aaron, Hunter, Danielle E., Tasche, Kendall K. , Moore, Eric J. , Neben-Wittich, M.A. , Price, Katharine A., Bayne, Harry E. Fuentes, Abel, Kathryn M. Van , Hidalgo, Cecelia M, Bogan, Aaron W, Bartemes, Kathleen R. , Neben-Wittich, Michelle A, Lester, Scott C. , McGarrah, Patrick W. , Fuentes Bayne, Harry E, Van Abel, Kathryn M , Yin, Linda X. , Price, Daniel L. , Daniel, J. , Routman, David M.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | May 14, 2025 | Volume: 151 | Issue: 12 | Pages: 1117

10.1001/jamaoto.2025.1606 | PMID 40367049 Get It

Importance Circulating tumor human papillomavirus DNA (ctHPVDNA) is an important biomarker for the presence of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), but little is known about early postoperative kinetics of ctHPVDNA clearance. Objective To investigate early postoperative kinetics of ctHPVDNA in patients with HPV-associated OPSCC. Design, Setting, and Participants This prospective cohort study was conducted at a single tertiary care center from January 4, 2020, to January 26, 2023. Patients with newly diagnosed HPV-associated OPSCC undergoing surgical management were enrolled. HPV status was defined as positive if findings of p16 immunohistochemistry and/or HPV DNA in situ hybridization and/or E6/E7 RNA in situ hybridization were positive. Exclusion criteria included history of prior head and neck cancer and metastatic disease at presentation. Data were analyzed from September 1, 2024, to April 25, 2025. Exposures Transoral robotic surgery with concurrent neck dissection. Main Outcomes and Measures Blood was drawn prior to surgery (pretreatment), 1 to 2 days after surgery (postoperative days 1 to 2), and approximately 2 weeks after surgery (postoperative week 2; range, 8 to 20 days). ctHPVDNA was quantified by a tumor tissue–modified viral (TTMV) HPV DNA test. Correlations were tested between the pretreatment and postoperative day 1 to 2 TTMV HPV DNA levels using Gaussian regression. Concordance between detectability at postoperative day 1 to 2 and postoperative week 2 was explored using negative predictive value and positive predictive value. Results Of 57 included patients with detectable pretreatment TTMV HPV DNA, 51 (89%) were male, and the median (IQR) age was 59 (54-66) years. A total of 35 patients (61%) had blood draws at all 3 time points; 16 (28%) had detectable TTMV HPV DNA on postoperative day 1 to 2. Pretreatment and postoperative day 1 to 2 TTMV HPV DNA levels had a medium positive linear correlation ( r = 0.31; 95% CI, 0.04-0.54). Undetectable TTMV HPV DNA on postoperative day 1 to 2 blood draw had a negative predictive value of 0.95 (95% CI, 0.74-1.00) for an undetectable level on postoperative week 2 blood draw, but a detectable level on postoperative day 1 to 2 blood draw only had a positive predictive value of 0.19 (95% CI, 0.04-0.46). Of the 16 patients with detectable TTMV HPV DNA pretreatment and at postoperative day 1 to 2, only 3 (19%) continued to have detectable TTMV HPV DNA at postoperative week 2. One patient had undetectable levels at postoperative day 1 to 2 and detectable levels at postoperative week 2. Conclusions and Relevance In this study, ctHPVDNA detectability early after surgery did not predict detectability at 2 weeks after surgery. ctHPVDNA clearance early after surgery could predict a negative test at 2 weeks. A negative blood draw finding on postoperative day 1 may be used to omit a postoperative blood draw at 2 weeks for minimal residual disease detection in future clinical trials.
The formal EU-US Meniscus Rehabilitation 2024 Consensus. An ESSKA-AOSSM-AASPT Initiative. Part I –Rehabilitation Management After Meniscus Surgery (Meniscectomy, Repair, Reconstruction)
Pujol, Nicolas , Giordano, Airelle O., Beaufils, Philippe , Monllau, Juan Carlos , Arhos, Elanna K. , Villa, Francesco Della, Goodloe, J. Brett , Irrgang, James J., Klosterman, Emma L. , Manske, Robert C. , Melick, Nicky van , Monson, Jill K. , Paterno, Mark V. , Piontek, Tomasz , Schmitt, Laura C. , Benjamin, C., Irrgang, James J. , Rambaud, Alexandre , Irrgang, James J , Arhos, Elanna K , Rambaud, Alexandre , Pujol, Nicolas , Giordano, Airelle O., Wong, Stephanie E. , Becker, Roland, Villa, Francesco Della, Klugarová, Jitka , Królikowska, Aleksandra , Krych, Aaron J. , LaPrade, Robert F. , Ostojić, Marko , Piontek, Tomasz , Perelli, Simone , Rambaud, Alexandre, Robinson, James Theodore , Senorski, Eric Hamrin , Snæbjörnsson, Thorkell , Tagliero, Adam J. , Prill, Robert

Mayo Clinic

International Journal of Sports Physical Therapy | May 12, 2025 | Volume: 20 | Issue: 6 | Pages: No page available

10.26603/001c.137095 Get It

Purpose The aim of part-one of this EU-US consensus was to combine literature research and expertise to provide recommendations for the usage of rehabilitation (including physical therapy) of patients undergoing surgical treatment for degenerative meniscus lesions or acute meniscus tears (including meniscectomy, repair, or reconstruction). Prevention programs, non-operative treatment of acute tears and degenerative lesions, return to sports and patient-reported outcome measures (PROMS) will be presented in a part-II article. Methods This consensus followed ESSKA “formal consensus” methodology. For this combined ESSKA (European Society for Sports Traumatology and Arthroscopy), AOSSM (American Orthopedic Society for Sports Medicine), ASSPT (American Academy of Sports Physical Therapy) initiative, 67 experts (26 in the steering group and 41 in the rating group) from 14 countries (USA and 13 European countries) including orthopedic surgeons, sports medicine doctors and physiotherapists were involved. Steering group members established guiding questions, searched the literature, proposed statements. Rating group members assessed the statements according to a Likert scale and provided grades of recommendations reaching final agreement about rehabilitation of the knee after meniscus surgery. Final documents were then assessed by a peer review group to adress the geographical adaptability. Results The overall level of evidence of the literature was low. Of the 19 questions (leading to 29 statements), one received a grade A of recommendation, two a grade B, nine a grade C and 17 a Grade D. Nevertheless, the mean median rating of all questions was 8.2/9 (9 being the highest rating on a scale of 1-9) and the global mean rating was 8.4+/-0.2, indicating a high agreement. Rehabilitation depends on the type of lesion, the treatment performed and is the same after medial or lateral meniscus surgery. Rehabilitation after meniscectomy should follow a criterion-based rehabilitation protocol, based on milestones rather than a time-based protocol. After meniscus repair and reconstruction, rehabilitation should be progressed according to both time and criterion-based milestones. Conclusion Rehabilitation after meniscus surgery is a debated topic that may influence surgical outcomes if not optimally performed. This international formal consensus established clear, updated, and structured recommendations for both surgeons and physiotherapists treating patients after meniscus surgery. Level of Evidence I, Consensus.
The formal EU‐US Meniscus Rehabilitation 2024 Consensus: An ESSKA‐AOSSM‐AASPT initiative. Part I—Rehabilitation management after meniscus surgery (meniscectomy, repair and reconstruction)
Pujol, Nicolas , Giordano, Airelle O., Beaufils, Philippe , Monllau, Juan Carlos , Arhos, Elanna K. , Villa, Francesco Della, Goodloe, J. Brett , Irrgang, James J., Klosterman, Emma L. , Manske, Robert C. , Melick, Nicky van , Monson, Jill K. , Paterno, Mark V. , Piontek, Tomasz , Rambaud, Alexandre , Schmitt, Laura C. , Benjamin, C. , Irrgang, James J. , Irrgang, James J , Arhos, Elanna K , Rambaud, Alexandre , Pujol, Nicolas , Wong, Stephanie E. , Becker, Roland, Villa, Francesco Della, Klugarová, Jitka , Królikowska, Aleksandra , Krych, Aaron J. , LaPrade, Robert F. , Ostojić, Marko , Piontek, Tomasz , Perelli, Simone , Robinson, James Theodore , Senorski, Eric Hamrin , Snæbjörnsson, Thorkell , Tagliero, Adam J. , Benjamin, C. , Prill, Robert

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | May 12, 2025 | Volume: 33 | Issue: 8 | Pages: 3002-3013

10.1002/ksa.12674 | PMID 40353298 Get It

Abstract Purpose The aim of part one of this EU‐US consensus was to combine literature research and expertise to provide recommendations for the usage of rehabilitation (including physical therapy) of patients undergoing surgical treatment for degenerative meniscus lesions or acute meniscus tears (including meniscectomy, repair, or reconstruction). Prevention programmes, non‐operative treatment of acute tears and degenerative lesions, return to sports and patient‐reported outcome measures will be presented in a part II article. Methods This consensus followed the European Society for Sports Traumatology and Arthroscopy (ESSKA)'s ‘formal consensus’ methodology. For this combined ESSKA, American Orthopedic Society for Sports Medicine and American Academy of Sports Physical Therapy initiative, 67 experts (26 in the steering group and 41 in the rating group) from 14 countries (US and 13 European countries), including orthopaedic surgeons, sports medicine doctors and physiotherapists were involved. Steering group members established guiding questions, searched the literature and proposed statements. Rating group members assessed the statements according to a Likert scale and provided grades of recommendations, reaching a final agreement about rehabilitation of the knee after meniscus surgery. Final documents were then assessed by a peer review group to address the geographical adaptability. Results The overall level of evidence in the literature was low. Of the 19 questions (leading to 29 statements), 1 received a Grade A of recommendation, 2 a Grade B, 9 a Grade C and 17 a Grade D. Nevertheless, the mean median rating of all questions was 8.2/9 (9 being the highest rating on a scale of 1–9). The global mean rating was 8.4 ± 0.2, indicating a high agreement. Rehabilitation depends on the type of lesion, the treatment performed and is the same after medial or lateral meniscus surgery. Rehabilitation after meniscectomy should follow a criterion‐based rehabilitation protocol, based on milestones rather than a time‐based protocol. After meniscus repair and reconstruction, rehabilitation should be progressed according to both time and criterion‐based milestones. Conclusion Rehabilitation after meniscus surgery is a debated topic that may influence surgical outcomes if not optimally performed. This international formal consensus established clear, updated and structured recommendations for both surgeons and physiotherapists treating patients after meniscus surgery. Level of Evidence Level I, consensus.
Antigen-specific Immunoprofiling in a Patient With Eisenmenger Syndrome, Treated Tuberculosis, and Atypical Non-tubercular Mycobacteria (NTM) Isolation Prior to Bilateral Lung Transplant
Lynn-Green, E., Pathakumari, Balaji , Keulen, Virginia P. Van , Peikert, Tobias, Pennington, Kelly M. , Escalante, Patricio , Gutierrez, L.E.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7894-A7894

10.1164/ajrccm.2025.211.abstracts.a7894 Get It

Abstract Non-tubercular mycobacteria (NTM) present a serious challenge in managing lung transplant candidates and recipients. Pretransplant NTM isolation has been associated with post-transplant NTM infection and significantly increased mortality risk. Strategies for managing pre-transplant NTM isolation vary widely in clinical practice. We present a 35-year-old lung transplant candidate from a tuberculosis-endemic country with severe pulmonary hypertension and Eisenmenger Syndrome due to unrepaired atrial septal defect, who underwent bilateral lung transplantation. Two years prior to transplant, she was successfully treated for pulmonary tuberculosis with six months of an unknown regimen in her home country. After moving to the U.S., she received M. tuberculosis (MTB) clearance from her state tuberculosis board, with three negative sputum samples six months prior to transplant. During her transplant evaluation, multi-drug-resistant M. fortuitum complex was isolated from one mycobacterial sputum culture. There was no clinical or radiographic evidence of active lung infection, and no targeted therapies were added. Standard peri-transplant antibiotics (vancomycin, cefepime, and caspofungin) were given. The patient received basilixamab for induction immunosuppression, and tacrolimus, mycophenolate mofetil, and prednisone for maintenance immunosuppression. Explant pathology showed necrotizing granuloma in the right upper lobe with acid-fast bacilli (AFB). The differential diagnosis included non-viable MTB, viable MTB despite prior clearance, or M. fortuitum. Three bronchoscopy washings were obtained in the first week post-transplant and returned negative for MTB by PCR, AFB stain, and culture. In collaboration with the Mycobacteriology laboratory, broad-range PCR testing was performed on the formalin-fixed paraffin-embedded samples from the explanted right lung, which was positive for MTB complex DNA. In total, the patient completed six sputum samples within the year pre-transplant and six respiratory samples within a month post-transplant, all of which returned negative for MTB by PCR, AFB stain, and culture. Blood flow cytometric (FC) immunoprofiling with mycobacterial antigens and controls was conducted (Escalante et al. 2015). The patient's FC antigen-specific activated T-cell profiling was consistent with a reduced risk of latent TB infection (FC CD4+ CD25+CD134+ T-cells (RD1-peptides-nil) = 0.19%). T-cell reactivity to MTB300 and PPD antigens suggested prior MTB, NTM, and/or BCG vaccination exposures. She progressed well without any preventive therapy for LTBI. FC immunoprofiling one year after transplantation showed similar results. She continues to have good pulmonary function and quality of life in her second-year post-transplant without evidence of NTM or MTB infection. Escalante P, et al. Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Am J Respir Crit Care Med. 2015;192(5):605-17. PMCID: PMC4595688.
Disruption of Microhomology-mediated End-joining in Ewing Sarcoma
Asada, Shuhei , Tanaka, Yutaro , Abeykoon, Jithma Prasad, Tanaka, Yutaro , Mukkavalli, Sirisha , Busso, Miles Del, Thangaiah, Judith Jebastin, Van Allen, Eliezer M , Shapiro, Geoffrey I , D'Andrea, Alan , Zhu, Guangli, Abeykoon, Jithma P. , Nguyen, Huy, Hirohashi, Yuna, Iyer, Divya , Ashton, Nicholas William , Mukkavalli, Sirisha , Velazquez, Martha, Jiang, Lige, Robinson, Steven I. , Parmar, Kalindi , Gillani, Riaz , Shapiro, Geoffrey I.

Mayo Clinic

No container title available | May 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.06.651696 | PMID 40568108 Get It

SUMMARY Ewing sarcoma (EwS) is a group of bone and soft tissue cancers in children and young adults. Since EwS cells have pronounced sensitivity to radiation and chemotherapy-induced DNA damage, the role of the oncoprotein, EWS-FLI1, in DNA repair is likely. Here, we demonstrate that EWS-FLI1 causes a defect in microhomology-mediated end-joining (MMEJ) repair. EWSR1 is a splicing factor that promotes the faithful splicing of the POLQ pre-mRNA, required for the expression of POLΘ, a critical protein in the MMEJ pathway. Expression of EWS-FLI1, or loss of EWSR1, causes exon 25 skipping of the POLQ transcript, decreased POLΘ expression, impaired MMEJ, and cellular sensitivity to inhibitors of the Fanconi Anemia (FA), NHEJ, or HR pathways, through the mechanism of synthetic lethality. Knockdown of EWS-FLI1 expression restores POL0 mitotic foci and increases MMEJ activity. Inhibitors of the FA, NHEJ, or HR therefore may provide a targeted therapy for patients with EwS. Highlights - Ewing sarcoma tumors have a deficiency in POLθ expression and a corresponding loss of MMEJ activity - EWSR1 is a splicing factor that interacts with other splicing factors such as FUBP1 and KHSRP/FUBP2 to accurately splice the POLQ mRNA. - The EWS-FLI1 fusion oncoprotein, or loss of EWSR1, causes a splicing defect, leading to exon25 skipping of the POLQ pre-mRNA and loss of POLθ expression - The MMEJ deficiency of EwS cells results in cellular sensitivity to inhibitors of Fanconi Anemia, Homologous Recombination or Non-Homologous End-Joining - Exon 25 skipping of POLQ mRNA is a predictive biomarker for HR inhibitors in human cancers
Global research aims for the study of cost and value in health professions education: A Delphi study of international experts
Tolsgaard, Martin G. , Nayahangan, Leizl Joy , Cook, David A. , Schalkwyk, Susan van , You, You , van Schalkwyk, Susan , You, Michelle You , Cleland, J , Tolsgaard, Martin , Madsen, Gorm Roager , Brydges, Ryan , Filho, Carvalho , Cleland, Jennifer

Mayo Clinic

Medical Teacher | May 10, 2025 | Volume: 47 | Issue: 11 | Pages: 1752-1760

10.1080/0142159x.2025.2501254 | PMID 40347090 Get It

A Proposal for HPV-Associated Oropharyngeal Carcinoma in the Ninth Edition Clinical TNM Classification
Huang, Shao Hui, Su, Jie , Koyfman, Shlomo A. , Hoebers, Frank , Bahig, Houda , Yu, Eugene , Bartlett, Eric , Davis, Robin L. , Woody, N.M. , Nelson, Kristoff , Lavigne, Danny , Nguyen‐Tan, Phuc Félix, Létourneau‐Guillon, Laurent , Filion, Édith, Nagelschneider, Alex A. , Abel, Kathryn M. Van , Postma, Alida A. , Palm, Walter M. , Lydiatt, William M. , Patel, Snehal G. , Routman, David, Van Abel, Kathryn M , Huang, Shao Hui, Routman, David M. , Spreafico, Anna , Lee, Jonathan Wei Jie , Stock, Sarah Jane , Daniel, J. , Hoeben, Ann , Chua, Melvin L.K. , Xu, Wei , O'Sullivan, Brian P

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | May 8, 2025 | Volume: 151 | Issue: 7 | Pages: 655

10.1001/jamaoto.2025.0848 | PMID 40338536 Get It

Importance A subset of Union for International Cancer Control ( UICC )/ American Joint Committee on Cancer ( AJCC ) eighth edition TNM stage I and II human papillomavirus–positive oropharyngeal carcinoma has undesirable outcomes, which might have contributed to a lack of success in phase III deintensification trials. Refining clinical stage groups, especially in the overabundant cN1/stage I group, has become important for treatment selection. Objective To assess the prognostic importance of pretreatment lymph node (LN) characteristics to optimize case distribution and outcome homogeneity within the N classification system. Design, Setting, and Participants This is an international multi-institutional retrospective prognostic cohort study. Analysis of human papillomavirus–positive oropharyngeal carcinoma treated curatively from 4 institutions (International Collaboration of Oropharyngeal Cancer Network for N-Classification [ICON-N] dataset) provided a refined clinical staging proposal; an independent dataset (Centre Hospitalier de l’Université de Montréal [CHUM] dataset) validated the proposal. Neuroradiologists reviewed pretreatment computed tomography and/or magnetic resonance imaging for nodal features, including presence or absence of abnormal LN(s), retropharyngeal LN, laterality, number of abnormal LN, and imaging-detected extranodal extension (iENE). Data were collected from February to May 2023, and data were analyzed from June to July 2023. Exposures Definitive chemoradiotherapy/radiotherapy or definitive surgery with or without postoperative chemoradiotherapy/radiotherapy. Main Outcomes and Measures The primary end point was overall survival. A Cox proportional hazards multivariable model was used to estimate adjusted hazard ratios (AHRs) and to derive an optimal clinical TNM stage classification (AHR-stage schema) incorporating the strongest prognostic nodal features within the UICC/AJCC eighth edition TNM framework after confirming the prognostication of iENE status. The performance (according to overall normalized scores and ranking) of the AHR-stage schema against the current UICC/AJCC eighth edition TNM staging system was evaluated for hazard consistency, hazard discrimination, prognostic importance, and sample size balance. Validation was performed in the CHUM dataset. Results The ICON-N dataset comprised 2053 patients, including 1898 (92.5%) with cN-positive disease and 155 (7.5%) with cN0 disease; a total of 298 (14.5%) were female, and the mean (SD) age was 60.6 (9.3) years. iENE-positive disease was identified in 710 of 1898 patients with cN-positive disease (37.4%). The median (range) follow-up was 5.1 (0.1-14.7) years. iENE was the strongest prognostic nodal feature in multivariable analysis; the AHR for iENE-positive vs iENE-positive disease was 2.43 (95% CI, 1.96-3.03) in the ICON-N dataset and 2.04 (95% CI, 1.28-3.23) in the CHUM dataset (n = 451). Reclassifying iENE-positive cases 1 stratum higher for N categorization without altering iENE-negative cases yielded an AHR-stage schema that outperformed the current TNM staging system in disease-free and overall survival with a lower (ie, better) overall normalized score (2 vs 3). Conclusions and Relevance In this study, reclassifying each N category 1 stratum higher for iENE-positive disease resulted in better disease-free and overall survival. The proposed new classification outperformed the currently TNM staging system in risk stratification and may facilitate future clinical trial design, outcomes research, and patient care.